Pharmacokinetics of gefitinib predicts the antitumor activity for advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Nakamura, Y.
Sano, K.
Fukuda, M.
Takatani, H.
Nagashima, S.
Kinoshita, A.
Fukuda, M.
Soda, H.
Oka, M.
Kohno, S.
机构：
[1] Goto Cent Hosp, Goto, Japan
[2] Meiji Pharmaceut Univ, Tokyo, Japan
[3] Nagasaki Thorac Oncol Grp, Nagasaki, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：81S / 81S
页数：1
相关论文
共 50 条
  • [31] IMPROVING TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Reck, M.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4038 - 4038
  • [32] Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?
    Sgambato, Assunta
    Casaluce, Francesca
    Maione, Paolo
    Rossi, Antonio
    Ciardiello, Fortunato
    Gridelli, Cesare
    JOURNAL OF THORACIC DISEASE, 2014, 6 (06) : 578 - 580
  • [33] Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib
    Chen Min-jiang
    Zhong Wei
    Zhang Li
    Zhao Jing
    Li Long-yun
    Wang Meng-zhao
    CHINESE MEDICAL JOURNAL, 2013, 126 (12) : 2235 - 2241
  • [34] Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib
    CHEN Min-jiang
    ZHONG Wei
    ZHANG Li
    ZHAO Jing
    LI Long-yun
    WANG Meng-zhao
    中华医学杂志（英文版）, 2013, 126 (12) : 2235 - 2241
  • [35] Effectiveness and cost of gefitinib in advanced/metastatic non-small cell lung cancer
    Selvi-Sabater, P.
    Sanchez-Martinez, I.
    Sadyrbaeva-Dolgova, S.
    Portillo-Haro, S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (01) : 289 - 289
  • [36] ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT
    Goncalves, Ivone M.
    Monteiro, Regina
    Neves, Sofia
    Conde, Sara
    Campainha, Sergio
    Parente, Barbara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1298 - S1298
  • [37] Gemcitabine and cisplatin for advanced non-small cell lung cancer (NSCLC)
    Casal, J
    Grande, C
    Caeiro, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1083 - 1083
  • [38] EGFR mRNA expression detected by RT-PCR predicts sensitivity to gefitinib in advanced non-small cell lung cancer (NSCLC) patients.
    Dziadziuszko, R
    Witta, S
    Cappuzzo, F
    Franklin, WA
    Crino, L
    Bunn, P
    Varella-Garcia, M
    Danenberg, KD
    Hirsch, FR
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9028S - 9029S
  • [39] Tolerability and activity of weekly paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC)
    Fabi, A
    De Marco, S
    Barduagni, M
    Gamucci, T
    Cortesi, E
    De Marinis, F
    Ferraresi, V
    Saltarelli, R
    Gabriele, A
    Accettura, C
    Cognetti, F
    ANNALS OF ONCOLOGY, 2000, 11 : 4 - 4
  • [40] Palliative treatment with gefitinib (G) in advanced and heavy pre-treated non-small cell lung cancer (NSCLC).
    Papi, M
    Tassinari, D
    Pasquini, E
    Genestreti, G
    Roudnas, B
    Fochessati, F
    Poggi, B
    Fantini, M
    Polselli, A
    Ravaioli, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 693S - 693S
12345